AAD 2023 – UCB and Acelyrin take aim at hidradenitis suppurativa
But Humira remains the one to beat.
ACC 2023 – Merck reaches for the stars
The Stellar trial of sotatercept lives up to its name, but the asset did not come cheap.
Sanofi and Regeneron face a high-risk test for Dupixent
A pivotal readout approaches in COPD, where other biologicals have fallen short.
Spotlight – still plenty of hopefuls in lung fibrosis
Roche’s zinpentraxin alfa is out of the running, but Bristol, Blade, Pliant and others have contenders in the mid-stage idiopathic pulmonary fibrosis pipeline.
The next big tests for Argenx and its followers
Some believe that blocking FcRn has TNF-like potential, and J&J, Immunovant and UCB are all hot on Argenx’s heels.
Biohaven looks to seize a new opportunity
The post-Pfizer pipeline looks disparate, but the group insists there is a method to its fast-follower approach.
